Table 2 Subgroup Analysis according to baseline characteristics of enrolled population for 12 weeks % reduction in laboratory endpoints
Total cholesterol at 12 weeks | LDL-C reduction at 12 weeks | Non-HDL-c reduction at 12 weeks | Apo B reduction at 12 weeks | Hs-CRP reduction at 12 weeks | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MD (%) | 95% CI | P value | MD (%) | 95% CI | P value | MD (%) | 95% CI | P value | MD (%) | 95% CI | P value | MD (%) | 95% CI | P value | |
High CV risk | − 10.8 | − 12.8 to − 8.8 | < 0.001 | − 17.8 | − 18.4 to − 17.2 | < 0.001 | − 19.0 | − 23.3 to − 14.6 | < 0.001 | − 14.0 | − 15.9 to − 12.1 | < 0.001 | − 19.4 | − 30.5 to − 8.3 | < 0.001 |
Hypercholesterolemia | − 19.7 | − 34.6 to − 4.8 | 0.01 | − 29.0 | − 46.4 to − 11.6 | < 0.001 | − 24.0 | − 41.9 to − 6.0 | 0.009 | − 27.2 | − 28.6 to − 25.9 | < 0.001 | − 39.4 | − 41.0 to 37.8 | < 0.001 |
Statin intolerant | − 16.6 | − 17.6 to − 15.6 | < 0.001 | − 22.0 | − 24.8 to − 19.2 | < 0.001 | − 19.8 | − 23.3 to − 16.2 | < 0.001 | − 19.1 | − 22.9 to − 15.2 | < 0.001 | − 29.1 | − 34.6 to − 23.6 | < 0.001 |